Key takeaways
- Semaglutide is a GLP-1 receptor agonist that mimics a natural gut hormone to lower blood sugar, slow digestion, and reduce appetite. It is FDA-approved and sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management.
- In the STEP 1 obesity trial, adults on the 2.4mg weekly dose lost about 15% of their body weight over 68 weeks, compared with about 2% on placebo.
- In people with type 2 diabetes at high cardiovascular risk, semaglutide reduced the rate of major cardiovascular events.
- The SELECT trial extended that finding to people with obesity but without diabetes, where semaglutide cut major cardiovascular events by about 20%, the first weight-loss medication shown to do so.
- It comes as a once-weekly injection or a daily tablet, and, like all GLP-1 therapies, works best alongside diet, activity, and medical supervision.
What is semaglutide?
Semaglutide is a once-weekly injectable, also available as a daily tablet, in the GLP-1 receptor agonist class. Unlike many of the compounds discussed in these articles, it has a large body of phase 3 evidence and full regulatory approval behind it. It is FDA-approved and widely prescribed: as Ozempic and Rybelsus for type 2 diabetes, and as Wegovy for chronic weight management.
Because it has been studied in tens of thousands of people across long trials, semaglutide is one of the most thoroughly documented metabolic medicines available today. That evidence base is what the sections below draw on.
How it works
Semaglutide mimics GLP-1, an incretin hormone the gut releases after a meal. Activating the GLP-1 receptor does several things at once. It prompts the pancreas to release insulin when blood sugar is high, lowers the counter-regulatory hormone glucagon, slows the rate at which the stomach empties, and acts on appetite centers in the brain to increase fullness and reduce hunger.
Together these effects improve blood-sugar control and lower calorie intake, which is why the same molecule helps both diabetes and weight management. Its once-weekly dosing comes from a molecular design that resists rapid breakdown and binds to albumin in the blood, which extends how long it stays active in the body.
What the research shows
The evidence is unusually strong for this class. In the STEP 1 trial (1,961 adults with obesity, published in the New England Journal of Medicine in 2021), the 2.4mg weekly dose produced a mean body-weight reduction of 14.9% at 68 weeks, compared with 2.4% on placebo. That is a large and durable effect from a medication rather than surgery.
On the metabolic and heart side, the SUSTAIN-6 trial in 2016 studied people with type 2 diabetes at high cardiovascular risk and found that semaglutide reduced the rate of major cardiovascular events. The landmark SELECT trial, published in 2023, went further: in more than 17,000 adults with overweight or obesity and established heart disease but without diabetes, semaglutide reduced major cardiovascular events by about 20%. It was the first time a weight-management medication was shown to lower cardiovascular risk in this group.
An oral form was tested in PIONEER 6, which supported the cardiovascular safety of daily oral semaglutide in type 2 diabetes, and a pooled analysis of the SUSTAIN 1-7 program summarized its blood-sugar and weight effects across seven trials. Taken together, these are consistent, large-scale results across blood sugar, weight, and cardiovascular outcomes.
What it is used for
Based on its approvals and the published research, semaglutide is used for blood-sugar control in type 2 diabetes (Ozempic and Rybelsus), for chronic weight management (Wegovy), and, following the SELECT results, for reducing cardiovascular risk in adults who have obesity and established heart disease. It continues to be studied in related metabolic and cardiovascular conditions.
As with any effective metabolic therapy, the details matter. Weight loss includes both fat and lean tissue, gastrointestinal side effects are common early on and are managed by titrating the dose slowly, and results are best maintained alongside nutrition and resistance training. Whether semaglutide is appropriate for any individual is a question for a qualified physician after a full assessment.
The evidence
Selected references, each verified against primary sources (PubMed, ClinicalTrials.gov, and FDA labeling). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Semaglutide is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Prescription medicines should be used only under the care of a licensed physician and according to their approved labeling. Any treatment decision should be made with a qualified physician. Individual results vary.